# Jin‐Ji Yang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jin-ji-yang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,155 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 50 |
| i10-index | 111 |
| Last Known Institution | Guangdong Academy of Medical Sciences |
| OpenAlex ID | https://openalex.org/A5100688947 |
| ORCID iD | 0000-0002-8498-0119 |
| Works | 289 |

## Researcher papers

Showing 12 of 14.

- [Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma](https://scholariq.org/papers/potential-predictive-value-of-i-tp53-i-and-i-kras-i-mutation-status-for-response/)
- [Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy](https://scholariq.org/papers/unique-genetic-profiles-from-cerebrospinal-fluid-cell-free-dna-in-leptomeningeal/)
- [Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations](https://scholariq.org/papers/leptomeningeal-metastases-in-patients-with-nsclc-with-egfr-mutations/)
- [Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression](https://scholariq.org/papers/fusion-of-eml4-and-alk-is-associated-with-development-of-lung-adenocarcinomas/)
- [Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-2/)
- [Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study](https://scholariq.org/papers/erlotinib-versus-gemcitabine-plus-cisplatin-as-neoadjuvant-treatment-of-stage/)
- [Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/relative-abundance-of-i-egfr-i-mutations-predicts-benefit-from-gefitinib/)
- [Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)](https://scholariq.org/papers/erlotinib-as-second-line-treatment-in-patients-with-advanced-non-small-cell-lung/)
- [Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study](https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/)
- [Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer](https://scholariq.org/papers/longitudinal-undetectable-molecular-residual-disease-defines-potentially-cured/)
- [A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival](https://scholariq.org/papers/a-potential-treatment-option-for-transformed-small-cell-lung-cancer-on-pd-l1/)
- [Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer](https://scholariq.org/papers/expression-of-egfr-mutant-proteins-and-genomic-evolution-in-egfr-mutant/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Guangdong Academy of Medical Sciences](https://scholariq.org/institutions/guangdong-academy-of-medical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.